The authors noted that ‘...clinical use of the V600E BRAF antibody should be a valuable supplement to conventional mutation testing and allow V600E mutant metastatic melanoma patients to be triaged rapidly into appropriate treatment pathways.’ Further support for this conclusion was provided by a study by Pearlstein et al, who compared VE1 immunostaining results with pyrosequencing results in 76 patients with melanoma.111 A total of 27 patients (35%) had the V600E mutation, and another nine had an alternate mutation (V600K, V600R, or V600Q). This evidence concerns the gene BRAF and melanoma.